CompletedPhase 2NCT02363751
Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)
Studying Collecting duct carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UNICANCER
- Principal Investigator
- Constance THIBAULT, DrHôpital Européen Georges-Pompidou
- Intervention
- Bevacizumab(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2020
Study locations (19)
- Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers, France
- CHU Besançon, Besançon, France
- Hôpital Saint André, Bordeaux, France
- Centre François Baclesse, Caen, France
- Hôpital Henri Mondor, Créteil, France
- Centre Oscar Lambret, Lille, France
- Centre Léon Bérard, Lyon, France
- Institut Paoli-Calmettes, Marseille, France
- ICM Val d'Aurelle, Montpellier, France
- Centre Antoine Lacassagne, Nice, France
- Hôpital Saint-Louis, Paris, France
- Hôpital Européen Georges Pompidou, Paris, France
- Centre Eugène Marquis, Rennes, France
- Centre Eugene Marquis, Rennes, France
- Institut de cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02363751 on ClinicalTrials.govOther trials for Collecting duct carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06302569Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary CarcinomaGiuseppe Procopio
- RECRUITINGPHASE2NCT06211114Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct CarcinomaPeking University Cancer Hospital & Institute